ExonHit Announces Termination of Agreement to Acquire RedPath
Advertisement
ExonHit Therapeutics announced the termination of the Combination Agreement for the acquisition of RedPath Integrated Pathology, Inc. Following Highmark’s recent decision to limit coverage of RedPath PathFinderTG® family of tests to the pancreatic cancer test only, the two companies were unable to agree on revised financial terms and conditions.
To accelerate its development as an internationally recognized diagnostic player, ExonHit is committed to pursuing its strategy of development via external growth and maintains its objective to acquire a revenue-generating molecular diagnostic company. Proceeds of the December 2009 capital increase will serve that purpose.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Emil Erlenmeyer and the Erlenmeyer Flask
Adam's_Curse
Angiogenesis_inhibitor
Tropical_disease

Inherited mutation leads to overproduction of EPO
Hypovolemia
List_of_locust_species
